Inhibiting PRPK reduces skin hyperplasia, angiogenesis, and cutaneous squamous cell carcinoma by blocking PRPK activation and lowering expression of proliferation and tumor markers such as cyclin D1, COX-2, and MMP-9 132. Here, MMP9 is linked to neoplasm.